A GAME-CHANGER FOR CHOOSING CANCER THERAPY HAS BEEN DEVELOPED THAT’S BEING CALLED A “BREAKTHROUGH, FIRST-OF-ITS-KIND LIVE CANCER TISSUE PROFILING” THAT PREDICTS THE MOST EFFECTIVE CANCER THERAPY FOR ANY GIVEN PATIENT. WE SPEAK WITH DR. CHRIS APFEL, FOUND & CEO OF “SAGE-MEDIC” DIAGNOSTIC CANCER TESTING COMPANY.
Want to know more about American Medicine Today?Full Bio